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Abstract
Intimate partner violence (IPV) is increasingly understood as an important public health
issue. It is well understood that intimate partner violence has many negative effects on its
survivors ranging from physical to mental health conditions. The population of people who
experience intimate partner violence and population of pregnant women are both vulnerable
populations. Examining the two populations together demands a trauma-informed approach and
an understanding of the intricacies of both pregnancy and intimate partner violence. While IPV
has been studied among the pregnant population, intimate partner violence as it relates to the
maternal fetal medicine (MFM) or high-risk pregnancy population is not yet well understood.
The purpose of this study is to describe the prevalence and effects of IPV among the MFM
population at the Methodist Perinatal Center in Omaha, NE. This study analyzed secondary data
obtained through the Abuse Assessment Screen (AAS) that was incorporated into the electronic
medical record (EMR) at Methodist Perinatal Center. Data were input into SPSS from which
descriptive statistics and a bivariate analysis (Chi square test) were entered. This study found that
5.6% of patients at Methodist Perinatal Center have experienced IPV. Further, this study found
that seven maternal and fetal health outcomes are associated with IPV including: BMI ≥25, STI,
psychiatric disorder, birth weight < 2.499kg, ultrasound anomaly, non-employer-based insurance
(self-pay and Medicaid), and non-married status These results show that it is important to screen
for IPV in the high-risk pregnancy setting. As this study shows that IPV occurs and negatively
affects women and their children, there is a need for further research on the effects of IPV and
development of interventions for the high-risk pregnant population.
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Chapter 1: Introduction
Research Question and Aims
The objective of this study is to determine the prevalence of intimate partner violence
(IPV) among women with a high-risk pregnancy at the Methodist Perinatal Center in Omaha,
NE. IPV is defined as, “physical violence, sexual violence, stalking and psychological
aggression (including coercive acts) by a current or former intimate partner,” (CDC, 2017b). The
population being studied is the Maternal Fetal Medicine (MFM) obstetrics population. The MFM
population consists of the high-risk pregnancy population. A high-risk pregnancy is “one that
threatens the health or life of the woman or her fetus” (Society for Maternal Fetal Medicine,
2018). The current medical literature on IPV in pregnancy has largely focused on low to averagerisk pregnancy. Since the literature on IPV in high-risk obstetrics populations is lacking, this
study aims to determine just how prevalent it is for women to experience IPV during a high-risk
pregnancy. Specifically, the primary research question is: what is the prevalence of IPV at the
Methodist Perinatal Center? Secondary objectives for this study include examining the risk
factors for IPV and whether the existing IPV is associated with adverse pregnancy outcomes
and/or adverse fetal outcomes.
Significance
High risk pregnancies can be variable as some women are at an increased risk for
complications before they become pregnant and some are identified as high risk as the pregnancy
develops. Risk factors for high-risk pregnancy include pre-existing health conditions prior to
pregnancy such as obesity, multiple gestations, HIV positive status, hypertension, teenage
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pregnancy, advanced maternal age, or diabetes mellitus (Eunice Kennedy Shriver National
Institute of Child Health and Human Development, 2017). The effects of IPV on pregnant
women, including high-risk pregnant women, are varied and potentially life-threatening.
According to the South Atlantic Association of Obstetricians and Gynecologists, IPV has many
effects on a pregnant woman both physically and mentally including: bone fractures, lacerations
and head trauma, sexually transmitted infections and unintended pregnancies, pain disorders, and
higher rates of depression, anxiety, posttraumatic stress disorder, and suicide (Chisholm et al.,
2017a). Zachor et al. (2018) also report that IPV in pregnancy is associated with sexually
transmitted infections, mental health disorders, pain disorders, gastrointestinal disorders, and
small for gestational age infants. Additionally, Hossieni et al. (2017) found that women who
experience IPV during pregnancy are at a higher risk of fearing birth. Adverse fetal outcomes
include small for gestational age, preterm birth, and low birthweight. Additionally, in several
parts of the United States, IPV can lead to suicide and homicide which are leading causes of
pregnancy-associated mortality (Chisholm et al., 2017a). Clearly, IPV can have very serious, and
potentially fatal, consequences for a pregnant woman and the developing fetus.
One of the first reviews of the prevalence of IPV in pregnancy in the United States found
the prevalence of IPV in pregnancy to be 0.9-20.1%; this wide range was interpreted to be due to
variety in survey instrument, study population, and study methods (Gazmararian et al., 1996).
Similarly, more recent estimates of the prevalence of IPV vary widely from 3-30% (Devries et
al., 2010). Most studies report a range of 3.9-8.7% (Van Parys et al., 2014). More recently, a
2009-2010 survey of women in a 30-state area found that the prevalence of IPV among the nonMFM pregnant population was 3.2% (Chisholm et al., 2017a). In 2017, according to the CDC
Pregnancy Risk Assessment Monitoring System (PRAMS), 2.2% of women experienced IPV
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during pregnancy (CDC, 2017a). The PRAMS survey estimates IPV in pregnancy by asking two
questions. Question one asks: “during your most recent pregnancy, did any of the following
people push, hit, slap, kick, choke or physically hurt you in any other way?” Participants select
my husband or partner, my ex-husband or ex-partner, another family member, and/or someone
else. The second question asks, “during any of the following time periods, did your husband or
partner threaten you, limit your activities against your will, or make you feel unsafe in any other
way?” Participants are asked to indicate during the 12 months before I got pregnant, during my
most recent pregnancy, and/or since my new baby was born (CDC, 2017a). Currently, there are
no estimates as to the prevalence of IPV in the MFM population; this study aims to establish the
prevalence at Methodist Women’s Hospital in Omaha, NE to establish a baseline prevalence
upon which further research will contribute.
Chapter 2: Background and Literature Review
A complete understanding of IPV requires a discussion of the prevalence of violenceparticularly IPV- in the United States. According to the National Intimate Partner and Sexual
Violence survey, 1 in 3 women experience violence in their lifetime including 1 in 10 women
being raped and 1 in 3 being physically abused (Breiding et al., 2011). Nearly 50% of women
and men experience psychological abuse from an intimate partner (Anyikwa, 2016). For
pregnant women, a 2009-2010 survey of women in a 30-state area found that the prevalence of
IPV among the non-MFM pregnant population was 3.2% (Chisholm et al., 2017a).
Further, women who experience IPV are exposed to trauma which occurs when
maladaptive behaviors replace a person’s normal ways of coping based on a person’s experience
of an event (Anyikwa, 2016). Therefore, when working with patients who have experienced IPV,
it is important to consider trauma. The concept of a trauma-informed approach has existed in the
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social work pedagogy for some time. A trauma-informed approach shifts from seeing behavior as
pathological to recognizing behavior as “strengths-based” and emphasizes the resilience of
survivors of IPV (Anyikwa, 2016, pg. 487). The goals of a trauma-informed approach and
trauma-informed care (TIC) is to reduce symptoms and work with patients towards recovery
(Anyikwa, 2016). The Substance Abuse and Mental Health Services Administration created a
trauma-informed framework which operates based on four assumptions and six principles
(Substance Abuse and Mental Health Services Administration, 2014). The assumptions are as
follows: realization of trauma, recognition of trauma, response to trauma, and resisting retraumatization. The principles are: emotional and physical safety of the patient; trustworthiness
and transparency; peer support; collaboration and mutuality; empowerment; voice and choice;
and cultural, historical and gender issues (Anyikwa, 2016). When working with patients in any
capacity, it is important to keep a trauma-informed approach in mind.
Many studies have examined risk factors and predictors of IPV among pregnant women.
Researchers in South Korea found several predictors of IPV such as unintended pregnancy, age,
employment status, and the level of education (Lee et al., 2017). Another study found that among
American women, an unplanned pregnancy and having parents with less than a high-school
education (indicating a lower socioeconomic status) were risk factors for pregnant women
experiencing IPV. This study found that older age and status as “married” were protective factors
for IPV in pregnancy; in other words, younger women and single women are at higher risk for
IPV (Yakubovich et al., 2018). According to the Behavioral Risk Factor Surveillance System,
evidence exists that health disparities according to race/ethnicity, education, income, and age
affect a person’s risk for experiencing IPV (Chisholm et al., 2017a).
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Further, a meta-analysis examining multiple studies of IPV in pregnancy identified seven
victim risk factors often examined in studies including: lifetime exposure to violence, alcohol
abuse, abuse prior to pregnancy, single status, lower educational attainment, unwanted
pregnancy, and low socioeconomic status (James et al., 2013). Five of the studies examined by
the meta-analysis found additional risk factors for IPV in pregnancy including lack of social
support, drug abuse, and race (James et al., 2013). The meta-analysis also identified two main
perpetrator risk factors among the studies which included unintended pregnancy and alcohol
abuse (James et al., 2013). One study examined past experiences of family violence with regard
to future risk of experiencing IPV in pregnancy and found that women who experience violence
perpetrated by their family members are at high risk for IPV during their pregnancy (Ludermir et
al., 2017). As such, there is strong evidence in the literature that there are many risk factors for
IPV in pregnancy as well as some evidence of risk factors for perpetrators of IPV.
An important subset of the literature surrounding IPV in pregnancy focuses on screening
for IPV. Studies often examine what screening methods are most appropriate for IPV in
pregnancy. According to The American Journal for Obstetrics and Gynecologists, screening is a
method to identify a disease that has not yet been diagnosed in patients with no signs or
symptoms (Chisholm et al., 2017b). In the pregnant population, the value of screening for IPV is
emphasized to improve patient quality of life by way of reducing future violence and improving
pregnancy outcomes (Chisholm et al., 2017b). All major health organizations that work in
women’s health including the WHO, ACOG, the IOM, and the USPSTF recommend screening
for IPV in pregnancy (Chisholm et al., 2017b).
There are several screening methods for IPV including the HITS, Woman Abuse
Screening Tool, HARK tool, and Abuse Assessment Screen, all of which have been used in
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pregnant women (Chisholm et al., 2017b). The HITS survey was developed for outpatient
clinical settings; HITS is an acronym standing for hits, insults, threatens, and screams. There are
four questions which are answered on a five-point scale in while one equals never and five
equals frequently. The survey asks: since you were pregnant, has a partner or ex-partner
physically hurt you, insulted you fairly often, threatened you, or screamed at you fairly often?
(Bailey, 2010). The Women Abuse Screening Tool (WAST) is an eight-question survey that
address emotional, physical, and sexual abuse; each question has three possible responses scored
0-2 with 0 being no tension, no difficult, never and 2 being a lot of tension, great difficulty, or
often. A score of ≥4 suggests exposure to IPV (Brown et al., 1996; Fletcher et al, 2016). The
HARK screen was adapted from the AAS and consists of 4 questions of self-report (yes or no)
relating to IPV. There is no pregnancy-specific question in the HARK tool (Sohal et al., 2007;
Fletcher et al., 2016).
Moreover, one study examined training of nurses to recognize IPV on an antepartum unit.
This particular study showed that after training nurses to recognize IPV, knowledge of IPV and
the protocol to follow increased and was well-received by the nursing staff (Bermele et al.,
2018). In another study, a training program for primary care providers was analyzed and showed
that compared to no training, training providers about IPV increased provider communication
about IPV (Zachor et al., 2018). Therefore, the literature reveals that training programs for all
health care providers is effective and can increase screening for IPV in pregnancy.
Effects of Intimate Partner Violence
The literature has established a myriad of effects of IPV on pregnant women. One study
found that patients who experienced IPV during pregnancy were more likely to experience poor
birth outcomes including preterm deliveries, low birth weight infants, and infants needing NICU
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care (Chen et al., 2017). Another study among women in Ethiopia found an association between
IPV and low birth weight of the infant (Laelago et al., 2017). Yet another study on the effects of
IPV on breastfeeding found that women who reported IPV during pregnancy were less likely to
continue to breastfeed more than six weeks postpartum (Miller- Graff et al., 2018). Overall, it is
clear from the studies reviewed that several forms of poor birth outcomes are associated with
IPV during pregnancy, further bolstering the need to screen for and prevent IPV in pregnancy.
There is conclusive evidence that IPV during pregnancy is a very serious phenomenon
affecting many women worldwide. Not only has research identified IPV in pregnancy as an issue
worthy of further research, but there is also adequate evidence that there are many well-identified
negative effects of IPV in pregnancy (Chisholm et al., 2017a; Zachor et al., 2018; Chen et al.,
2017; Laelago et al, 2017). It has been shown that standardized, routine clinical assessment is
important to intervene in current abuse and, potentially, prevent future abuse (McFarlane et al.,
1992). Additionally, there is evidence that screening for IPV in pregnancy is beneficial and that
there are several tools available for effective screening of IPV in pregnancy (Chisholm et al.,
2017b; Macfarlane et al., 1992; Van Parys et al., 2017; Webster et al., 2017; O’Reilly et al.,
2010). Furthermore, several training programs have provided increased screening for IPV in
pregnancy by all members of the health care team. Finally, there have been many studies
examining the negative birth outcomes related to IPV during pregnancy.
However, further research is needed to determine how common the issue of IPV is among
the high-risk obstetrics population as current medical research on IPV among the MFM
population is lacking. It is reasonable to hypothesize that the addition of another risk factor for
adverse pregnancy outcomes such as IPV to an already high-risk pregnancy would likely
increase that high-risk pregnancy’s risk for adverse outcomes. Unfortunately, the medical
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literature has yet to examine this hypothesis in depth. This study aims to fill this gap in the
literature.
This project will most benefit women, pregnant women, and high-risk obstetrics populations.
The accumulation of these populations would account for almost every woman during her
lifetime should she decide to or be able to reproduce. The population estimate of Omaha, NE
during the study was 468, 262. As such, this study could potentially affect approximately 50% of
the population in Omaha or approximately 230,000 women (United States Census Bureau,
2017). More specifically this study focuses on pregnant women. According to Life Course
Theory, any study involving women, such as this one, has the ability to be interpreted through a
wide lens. Life Course Theory “refers to the sequence of events and roles- age-graded, socially
defined, and nested within historical time and place- that forms our individual biographies,”
(Kotch, 2013, pg. 68). There are three key concepts in life course theory: trajectories, transitions,
and turning points. Trajectories describe health and well-being for a substantial period of a
person’s life. Transitions are phases that are often associated with a change in health status and
often occur over a brief time period. Turning points are changes in trajectories through changes
in behavior or situation (Kotch, 2013). Pregnancy is a very common transition in a person’s life
that can positively or negatively alter that person’s trajectory. From a life course perspective, the
impact of this study is quite broad as the principle of life span development takes into account
the cumulative effect of health over a person’s lifetime as well as generational effects (Kotch,
2013). Additionally, this study’s findings impact the entire population as a whole as pregnant
women generate the next generation of a society.
The primary goal of this study is to estimate baseline data on the prevalence of IPV in a highrisk obstetrics population. A literature review was performed in PubMed, EBSCO, and Google
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Scholar searching for the prevalence of IPV in the MFM population using the search terms
“intimate partner violence” and “maternal fetal medicine” and “high-risk pregnancy” and yielded
no results; based on a search of the current literature, there are no current estimates of the
prevalence of IPV in the MFM population. The secondary aim is to determine whether the IPV
that exists causes adverse pregnancy outcomes and/or poor birth outcomes. The long-term goal
would be to determine the adverse effects of IPV on high-risk pregnant women and finally how
to intervene and prevent women from experiencing IPV in pregnancy or how to intervene as IPV
is occurring. Only then could intervention efforts be undertaken. Indeed, research has shown
empowerment intervention to be evidence-based in decreasing violence among the pregnant
population over time (Chisholm et al., 2017b). This study will provide valuable knowledge about
a vulnerable population, high-risk obstetrics, that will inform future scholarship that will lead to
lasting change regarding the prevalence of IPV. Specifically, the questions for this study are:
Research Question 1: What is the prevalence of IPV in a high-risk obstetrics population?
Research Question 2: Is IPV associated with adverse pregnancy outcomes and/or poor birth
outcomes?
Chapter 3: Data and Methods
Study Design, Setting, and Study Population
This study is a retrospective cross-sectional study. A cross-sectional study fits this
research question best as the study seeks to determine how many women are affected by IPV at
one hospital in Omaha, NE. The Methodist Perinatal Center started screening every patient at
their first obstetrics visit for IPV in January 2019 using the Abuse Assessment Screen. The
population of this study was the Maternal Fetal Medicine (MFM) obstetrics population at the
Methodist Perinatal Center at Methodist Women’s Hospital. The population for the current study
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consists of 1,069 patients who presented for their first obstetrics visit at Methodist Women’s
Hospital in Omaha, NE from January 2, 2019 to July 31, 2019.
The study sample was obtained by convenience sampling due to the sensitive nature of
the issue and the care health care workers must take when approaching the subject of IPV with
participants. It would be unwise if not unethical to screen participants for IPV in a less structured
environment with no access to resources. Specifically, since this is a clinical study, privacy and
HIPAA laws were followed. Further, according to the CDC Pregnancy Risk Assessment
Monitoring System (PRAMS), 2.2% of women experience IPV during pregnancy (CDC, 2017a).
For a sample size of 1,281 patients, the confidence interval is +/- 0.08 meaning that we expected
to find 1.4-3% of the patients included in this study to report positive for IPV.
A survey has been chosen as the measurement instrument as it provides more data in a
shorter amount of time than other instruments, such as qualitative interviews. The incorporation
of the screening into the normal clinic flow created access to as many participants as possible.
The method is also in line with past scholarship that has shown that a clinical provider
performing a simple screen with no partner present is effective in identifying patients who have
experienced IPV (McFarlane et al., 1992).
Variables and Operational Definitions
The primary outcome variable studied is intimate partner violence (IPV). The
independent variables include insurance provider, race, ethnicity, socioeconomic status, and
marital status. All of these factors could potentially affect a person’s risk for experiencing IPV.
Additionally, the control variable is age which restricted the study to patients age 19 and above.
In the state of Nebraska, the age of majority is 19; restricting children as study participants
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simplifies study design. The study population was restricted to patients at Methodist Women’s
Perinatal Center as that is the hospital where the survey was be administered.
Next, a potential confounding variable is participant understanding of “abuse” in the first
question of the survey: “Have you ever been physically or emotionally abused by your partner or
someone important to you?” The word abuse itself is open to interpretation as there was no
definition of abuse provided for the patient in the survey. The rest of the questions only focused
on physical abuse and behavior. Patients’ determination on whether or not they had experienced
IPV may have been influenced by these limitations. A last difficulty of this type of screening is
that staff were not trained specifically on how to ask questions and to respond to patients if they
had questions about the survey. If participants had questions, the responses they received might
have varied according to the ability level of staff.
Inclusion criteria included: women over the age of 19 and patients presenting for a first
obstetrics visit at the clinic. Exclusion criteria included patients under the age of 19, patients with
a triplet birth, and patients screened with the previously-used one-question screen. Patients under
age 19 were excluded as they are minors in Nebraska and this study was focused on adult highrisk obstetrics patients. Patients with triplet births were excluded as their outcomes are very
different from singleton and twin births. Patients screened with the previously-used one-question
screen were excluded as that was not the survey instrument being used in this study.
Data Sources and Measurement
The dependent variable, IPV, was measured by the Abuse Assessment Screen (AAS).
The Abuse Assessment Screen has been used widely in the pregnant population to screen for IPV
and is the standard survey method for IPV in the field of obstetrics (Chisholm et al., 2017a). The
AAS has a sensitivity and specificity of 93-94% and 55-99%, respectively (Chisholm et al.,
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2017b; Zachor et al., 2018). The AAS is a confidential, anonymous five-question survey that was
developed by McFarlane et al. (1992) to screen for IPV among the pregnant population. The
questions are as follows:
Question 1: “Have you ever been emotionally or physically abused by your partner or
someone important to you?”
Question 2: “Within the last year, have you been hit, slapped, kicked, or otherwise
physically hurt by someone?”
If the answer to question 2 is yes, the participant is prompted to select who the perpetrator of
violence is such as a husband, ex-husband, boyfriend, stranger, other, or multiple and then how
many times that violence occurred.
Question 3: “Since you’ve been pregnant, have you been hit, slapped, kicked, or
otherwise physically hurt by someone?”
If the answer to question 3 is yes, the participant is again prompted to select what relationship
they had to the perpetrator and how many times that violence occurred, to mark the area of injury
on a body map, and to score each incident using a 1-6 scale of severity with ‘one’ being threats
of abuse including the use of a weapon and ‘six’ being use of a weapon or wound from a
weapon.
Question 4: “Within the last year, has anyone forced you to have sexual activities?”
Patients are asked to specify by whom and how many times the forced sexual activities occurred.
Question 5: “Are you afraid of your partner or anyone you listed above?” (McFarlane et
al., 1992, p. 3177)
If a patient answers yes to any of the five questions, their response is recorded as positive for
IPV. The AAS is relatively short, thereby reducing survey fatigue. The survey also utilizes non-
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judgmental language which is a key tenet of trauma-informed care. In addition to the AAS,
deidentified demographic data from the electronic medical record was included in the data
review. This additional data included maternal health outcomes, fetal health outcomes, insurance
status (individual private pay, self-pay, or Medicare/Medicaid), employment status, age,
language, race, ethnicity, and marital status.
Furthermore, research question two asked: is IPV associated with adverse pregnancy
outcomes and/or poor birth outcomes? To answer research question two, the maternal health
outcomes that were examined were: preterm bleeding (PTB), maternal infection, preterm labor
(PTL), mode of delivery, progress of labor, premature rupture of membranes (PROM), preterm
premature rupture of membranes (PPROM), hospitalization before delivery, body mass index
(BMI), anemia, bone fracture, laceration, head trauma, sexually transmitted infection (STI), pain
disorder (chronic pain disorder, fibromyalgia, and endometriosis), and psychiatric disorder
(depression, anxiety, panic disorder, and PTSD). Fetal outcomes that were examined are birth
weight, gestational age, admission to a neonatal intensive care unit (NICU), APGAR scores at
one and five minutes after birth, and breastfeeding status. Birth weight was recorded as birth
weight A and B as twin births were included. For singleton births, birth weight A represents the
birth weight of the single neonate. For twin births, birth weight A and B represented birth weight
for baby A and baby B, respectively. Pregnancy conditions that were examined were: high risk
pregnancy (HRP), ultrasound abnormality (polyhydramnios and oligohydramnios), fetal anomaly
(chromosomal/genetic abnormalities, congenital heart disease), intrauterine growth restriction
(IUGR), gestational diabetes mellitus (GDM), intrauterine fetal demise (IUFD), spontaneous
abortion (SAB), hypertensive disorders of pregnancy (HTN DOP), history of SAB, history of
IUFD, history of HTN DOP, history of cesarean delivery (CD), other substance use (alcohol and
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illicit drug use), tobacco use, clotting disorder, seizure disorder, cardiac disease, renal disease,
thyroid disease, chronic hypertension (HTN), and diabetes mellitus (DM) which includes both
Type 1 and Type 2 diabetes.
Table of Abbreviations
PTB

Preterm bleeding

PTL

Preterm labor

PROM

Premature rupture of membranes

PPROM

Preterm premature rupture of membranes

BMI

Body mass index

STI

Sexually transmitted infection

NICU

Neonatal intensive care unit

HRP

High risk pregnancy

IUGR

Intrauterine growth restriction

GDM

Gestational diabetes mellitus

IUFD

Intrauterine fetal demise

SAB

Spontaneous abortion

HTN DOP

Hypertensive disorders of pregnancy

CD

Cesarean delivery

HTN

Hypertension

DM

Diabetes mellitus

Sample Size
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The size of the population of interest was 1,069. The sample size consisted of 967 patients
who met initial inclusion criteria. Then, 218 patients with missing delivery data were excluded.
Missing delivery data is defined as patients who delivered elsewhere, had not yet delivered,
and/or patients with incomplete delivery data in the EMR. After exclusion, the sample size was
749. Convenience sampling was achieved by collecting data from only one clinic. This also
limited time and personnel constrains as including other hospitals would require the participation
and cooperation from multiple departments and personnel, which is currently not feasible. As
this study is estimating prevalence among all patients who fulfilled the inclusion criteria, it was
not necessary to perform a power analysis.

Data Collection
IRB approval was obtained from Methodist Women’s Hospital August 29, 2019, and
from UNMC on September 20, 2019. Every new patient presenting to the maternal fetal
medicine clinic at Methodist Women’s Hospital in Omaha, NE for a first trimester obstetrics
visit was screened for IPV using the Abuse Assessment Screen survey. The AAS was integrated
into the electronic medical record and administered by nursing staff in a separate intake room at
the Methodist Perinatal Center starting January 1, 2019 and continuing until July 31, 2019.
Clinic staff asked the five AAS questions at the time of the patient visit; this data was then
reviewed in the electronic medical record. Every patient seeking care for a first trimester
obstetrics visit at the Perinatal Center at Methodist Women’s Hospital was screened.
This research was carried out following established ethical protocols. For example,
according to the SAMHSA trauma-informed framework, the principle of safety was emphasized
(Substance Abuse and Mental Health Services Administration, 2014). Per protocol, no family,
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friends, or significant others were allowed in the room at the time of screening to ensure
confidentiality. However, some patients had a support person in the room while the AAS was
administered; when this happened, the AAS questions were not asked. As a result, a third of
participants were not screened. The principles of trustworthiness and transparency were also
utilized; the clinic staff administering the screen were consistent and transparent with the
patients. The principles of collaboration and mutuality were also a part of the process. The clinic
staff have been trained in the era of recognizing patient autonomy which ensures that patients are
seen as experts in their own lives (Anyikwa, 2016). This screening was incorporated into the
regular clinic flow which assists to normalize the information being ascertained and attempts to
make the patients more at ease when answering sensitive questions. As stated earlier, a positive
screen was defined as the patient answering “yes” to any one of the five questions as has been
established in standard usage of the AAS (Zachor et al., 2018). If patients screened positive, staff
were instructed to provide clinical support and access to local resources such as the Women’s
Center for Advancement as nursing staff have not yet received trauma-informed care training.

Statistical Methods
Prior to data analysis, all patient information was de-identified. Summary statistics were
used to describe the frequency of variables and mean and standard deviation of the numerical
variables. A bivariate analysis was conducted to look for a relationship between IPV and any of
the independent variables. Chi-square tests were used to test for an association between IPV and
categorical independent variables. Independent t tests were run for age and BMI. For this study,
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IBM SPSS Statistics Subscription build number 1.0.0.1327 was utilized to perform the statistical
analyses (IBM SPSS Statistics for Macintosh, 2018).
Chapter 4: Results
Demographic Data
Table 1 includes demographic information including: insurance provider, language, race,
ethnicity, marital status, employment, age, and body mass index (BMI). There are two missing
variables for BMI as the BMI was incorrectly recorded for two patients; these values were
265.15 and 154.86 which were excluded. Body mass index was divided into patients with a
BMI≥25 or BMI<25 as a BMI that is greater than or equal to 25 is defined as overweight or
obese. This cutoff was chosen as it is clinically significant to be either a healthy weight or
overweight/obese. For age, an age greater than or equal to 35 is defined as advanced maternal
age. These cutoffs were reasoned to be clinically significant.
Table 1: Background Data (N=967)
Variable
Race
Asian
American Indian/Alaskan Native
Black
Multiple
Other
White
Unknown
Ethnicity
Hispanic
Multiple
Non-Hispanic
Other
Unknown
Preferred Language for Healthcare Information Delivery
Arabic

N (%)
27 (2.8)
8 (0.8)
44 (4.6)
40 (4.1)
25 (2.6)
816 (84.4)
7 (0.7)
60 (6.2)
17 (1.8)
864 (89.3)
1 (0.1)
25 (2.6)
1 (0.1)

Mean (SD)

Larsen 19
English
French
Other
Russian
Spanish
Vietnamese
Unknown
Marital Status
Divorced
Married
Single
Unknown
Insurance Provider
Employer-Based Health Insurance
Medicaid
Self-pay
Employment
Employed
Unemployed
Unknown
Age*
<35yo
≥35yo
BMI*
BMI <25
BMI ≥25
Missing
*N=749

943 (97.5)
1 (0.1)
5 (0.5)
2 (0.2)
10 (1)
2 (0.2)
3 (0.3)
24 (2.5)
734 (75.9)
195 (20.2)
14 (1.4)
776 (80.2)
177 (18.3)
14 (1.4)
757 (78.3)
201 (20.8)
9 (0.9)
32.15 (5.29)
461 (61.5)
288 (38.5)
29.42 (8.03)
265 (35.5)
484 (64.5)
2 (0.3)

Demographic Data After Exclusion of Missing Delivery Data
Table 2 is a summary of demographic information after exclusion of patients with
missing delivery data. In this table, the demographic data is split into two groups per variable
based on the group with the highest percentage of patients. For insurance provider, patients were
split into employer-based health insurance (EBHI) or non-employer-based health insurance.
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Language was divided into English and Non-English. Race was split into White and Non-White.
Ethnicity was split into Hispanic and Non-Hispanic. Marriage status was split into married and
non-married. The demographic data was split into two groups at this stage to allow for larger
group sample sizes. There was no missing demographic data after exclusion of patients with
missing delivery data.
Table 2: Demographics After Exclusion of Missing Delivery Data
N=749
N (%)
Race
White
642 (85.7)
Non-White
107 (14.3)
Ethnicity
Hispanic
693 (92.5)
Non-Hispanic
56 (7.5)
Preferred Language for Healthcare Information Delivery
English
732 (97.7)
Non-English
17 (2.3)
Marriage Status
Married
607 (81)
Non-married
142 (19)
Insurance Provider
EBHI
626 (83.6)
Non-EBHI
123 (16.4)
Missing

0 (0)

Descriptive Data
Descriptive data that was collected included frequencies of all variables and demographic
data. Patients with missing recorded delivery data likely only saw the MFM clinic for a consult
or delivered somewhere other than Methodist Women’s Hospital. The missing data column
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consists of patients with an AAS screen marked “unable to answer” which typically meant
someone other than the staff member and the patient was in the room.
Fetal Outcomes Before Exclusion of Patients with Missing Delivery Data
Table 3 includes the mean and standard deviation for fetal outcomes before exclusion of
patients with missing delivery data. Each variable was divided into two groups for bivariate
analysis based on clinical reasoning. For birth weight, low birth weight is designated as less than
2.499kg. For gestational age, a gestational age < 37 weeks is defined as preterm. For APGARs,
an APGAR of 5 was chosen as the distinction as that is clinically significant. All of these cutoffs
were reasoned to be clinically significant. Birth Weight was separated into birth weight A and B
as there were 67 twins recorded. For all births that were singletons, birth weight A is the
recorded weight for the singleton neonate. There are 900 missing values for Birth Weight B and
APGAR B1 and B5 as there were only 67 twins total. From Table 3, it is evident that most
patients gave birth at term to neonates of a normal birthweight with healthy APGAR scores. Of
note, baby B of a twin pair tended to have a lower birth weight and APGAR than baby A of twin
pairs. Table 4 includes fetal outcomes after exclusion of patients with missing delivery data.
Table 3: Fetal Outcomes Before Exclusion of Patients with
Missing Delivery Data
Mean (SD)
Birth Weight A (kg) n = 746
3.14 (0.74)
Birth Weight B (kg) n = 67
2.12 (0.75)
APGAR A1 n = 744
7.71 (1.63)
APGAR A5 n = 744
8.69 (1.39)
APGAR B1 n = 65
6.05 (2.85)
APGAR B5 n = 65
7.52 (2.49)
Gestational Age (GA) n=761
37.18 (4.07)

Fetal Outcomes After Exclusion of Patients with Missing Delivery Data
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Table 4: Fetal Outcomes After Exclusion of Patients
with Missing Delivery Data
N= 749
N (%)
BWA ≥2.499
631(85)
BWA<2.499
111(15)
Missing
7 (0.9)
BWB ≥2.499
BWB<2.499
Missing (Singleton births)

23 (34.3)
44 (65.7)
682 (91.1)

GA ≥37
GA<37
Missing

594 (79.3)
155 (20.7)
0

APGARA1 ≥5
APGARA1<5
Missing

697 (93.8)
46 (6.2)
6 (0.8)

APGARA5 ≥5
APGARA<5
Missing

726 (97.7)
17 (2.3)
6 (0.8)

APGARB1≥5
APGARB1<5
Missing (Singleton births)

49 (75.4)
16 (24.6)
684 (91.3)

APGARB5≥5
APGARB5<5
Missing (Singleton births)

54 (83.1)
11 (16.9)
684 (91.3)

Delivery Data
Table 5 includes delivery outcomes including: mode of delivery data broken down into
spontaneous vaginal delivery (SVD), operative vaginal delivery (OVD), primary cesarean
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delivery (PCD), repeat cesarean delivery (RCD), and dilation and evacuation (D&E) for
spontaneous abortions and intrauterine fetal demise. Table 5 also provides data for normal and
abnormal progress of labor. Abnormal labor is defined as the abnormal progression of labor;
abnormal progression of labor is defined as the observation of one of two abnormal labor
patterns (protraction or arrest disorder) (Casanova et al., 2019); abnormal progress of labor was
indicated by a record in the chart of prolongation of stage 2 of delivery.
Table 5: Delivery Outcomes
(N=967)
Spontaneous Vaginal Delivery
Operative Vaginal Delivery
Primary Cesarean Delivery
Repeat Cesarean Delivery
Dilation and Evacuation
Mode of Delivery (Missing)
Normal Progress of Labor
Abnormal Progress of Labor
Progress of Labor (Missing)

N (%)
967 (42.1)
30 (3.1)
153 (15.8)
160 (16.5)
10.0 (1.0)
207 (21.4)
414 (42.8)
63 (6.5)
490 (50.7)

Delivery Data After Exclusion of Missing Delivery Data
Table 6 includes delivery and progress of labor data after exclusion of patients with
missing delivery data. Patients were split into two groups at this stage for optimal data analysis.
For delivery data, patients were recorded as vaginal or cesarean delivery. Progress of labor was
recorded as normal or abnormal. Progress of labor is defined as abnormal if one of two abnormal
labor patterns (protraction or arrest disorder) are observed (Casanova et al., 2019). This table
shows no missing method of delivery. The missing progress of labor variable includes both
cesarean deliveries wherein progress of labor does not apply and patients whose charts did not
indicate progress of labor.
Table 6: Delivery Data After Exclusion of Missing Delivery Data
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Vaginal Delivery
Cesarean Delivery
Progress of Labor (Normal)
Progress of Labor (Abnormal)
Progress of Labor (Missing)

N (%) N=749
437 (58.3)
312 (41.7)
410 (86.7)
63 (13.3)
276 (36.8)

Pregnancy Condition Variables Before and After Exclusion of Patients with Missing
Delivery Data
Table 7 includes the 21 pregnancy condition variables that were recorded before and after
exclusion of patients with missing delivery data. After exclusion of patients with missing
delivery data, there were no missing values.
Table 7: Pregnancy Condition Variables Before and After Exclusion of Patients with Missing
Delivery Data
Before Exclusion (N=967)
After Exclusion (N=749)
Pregnancy
Yes N (%) No N (%)
Yes N (%)
No N (%)
Missing
Condition
High Risk Pregnancy 422 (43.6) 545 (56.4)
282 (37.7)
467 (62.3)
0
Ultrasound Anomaly 104 (10.8) 863 (89.2)
84 (11.2)
665 (88.8)
0
Fetal Anomaly
83 (8.6)
884 (91.4)
62 (8.3)
687 (91.7)
0
Intrauterine Growth 65 (6.7)
902 (93.3)
53 (7.1)
696 (92.9)
0
Restriction
Gestational
90 (9.3)
877 (90.7)
77 (10.3)
672 (89.7)
0
Diabetes Mellitus
Intrauterine Fetal
8 (0.8)
959 (99.2)
6 (0.8)
743 (99.2)
0
Demise
Spontaneous
7 (0.7)
960 (99.3)
1 (0.1)
748 (99.9)
0
Abortion
Hypertensive
122 (12.6) 845 (87.4)
114 (15.2)
635 (84.8)
0
Disorders of
Pregnancy
History of
29 (3)
938 (97)
25 (3.3)
724 (96.7)
0
Spontaneous
Abortion
History of
15 (1.6)
952 (98.4)
10 (1.3)
739 (98.7)
0
Intrauterine Fetal
Demise
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History of
Hypertensive
Disorders of
Pregnancy
History of Cesarean
Delivery
Other Substance
Use
Tobacco Use
Clotting Disorder
Seizure Disorder
Cardiac Disease
Renal Disease
Thyroid Disease
Chronic
Hypertension
Diabetes Mellitus

52 (5.4)

915 (94.6)

46 (6.1)

703 (93.9)

0

194 (20.1)

773 (79.9)

172 (23)

577 (77)

0

9 (0.9)

958 (99.1)

5 (0.7)

744 (99.3)

0

50 (5.2)
39 (4)
9 (0.9)
10.0 (1.0)
10.0 (1.0)
110 (11.4)
68 (7)

917 (94.8)
928 (96)
958 (99.1)
957 (99)
957 (99)
857 (88.6)
899 (93)

36 (4.8)
32 (4.3)
7 (0.9)
8 (1.1)
7 (0.9)
91 (12.2)
53 (7.1)

713 (95.2)
717 (95.7)
742 (99.1)
741 (98.9)
742 (99.1)
658 (87.9)
696 (92.9)

0
0
0
0
0
0
0

24 (2.5)

943 (97.5)

20 (2.7)

729 (97.3)

0

Maternal and Fetal Health Outcomes
Table 8 includes pregnancy outcomes and fetal health outcomes. Pregnancy outcomes
include preterm bleeding (PTB), maternal infection, preterm labor (PTL), premature rupture of
membranes (PROM), preterm premature rupture of membranes (PPROM), hospitalization before
delivery, anemia, bone fracture, laceration, head trauma, sexually transmitted infection, pain
disorder, psychiatric disorder, and multiple births. Patients with missing delivery data likely
delivered somewhere other than Methodist Women’s Hospital, had not yet delivered, or had
incomplete delivery data entered into the EMR. Table 8 fetal outcome data includes neonatal
intensive care unit (NICU) admission and breastfeeding status.
Table 8: Maternal and Fetal Health Outcomes
Before Exclusion (N=967)
Pregnancy
Yes N (%) No N (%)
Missing N
Outcomes
(%)
PTB
56 (5.8)
721 (74.6) 190 (19.6)

After Exclusion (N=749)
Yes N (%)
No N (%)
Missing N
(%)
47 (6.3)
702 (93.7)
0 (0)
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Maternal
Infection
PTL
PROM
PPROM
Hospitalization
Before Delivery
Anemia
Bone Fracture
Laceration
Head Trauma
STI
Pain Disorder
Psychiatric
Disorder
Multiples
NICU
Breastfeeding

11 (1.1)

758 (78.4)

198 (20.5)

10 (1.3)

739 (98.7)

0 (0)

64 (6.6)
5 (0.5)
36 (3.7)
145 (15)

705 (72.9)
759 (78.5)
728 (75.3)
624 (64.5)

198 (20.5)
203 (21)
203 (21)
198 (20.5)

58 (7.7)
5 (0.7)
35 (4.7)
141 (18.8)

691 (92.3)
744 (99.3)
714 (95.3)
608 (81.2)

0 (0)
0 (0)
0 (0)
0 (0)

58 (6)
0 (0)
2 (0.2)
2 (0.2)
42 (4.3)
49 (5.1)
186 (19.2)

882 (91.2)
940 (97.2)
938 (97)
938 (97)
892 (92.9)
892 (92.2)
757 (78.3)

27 (2.8)
27 (2.8)
27 (2.8)
27 (2.8)
26 (2.8)
26 (2.7)
24 (2.5)

54 (7.2)
0 (0)
2 (0.3)
2 (0.3)
34 (4.5)
45 (6)
151 (20.2)

695 (92.8)
749 (0)
747 (99.7)
747 (99.7)
715 (95.5)
704 (94)
598 (79.8)

0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)

76 (7.9)
158 (16.3)
650 (67.2)

883 (91.3)
583 (60.3)
43 (4.4)

8 (0.8)
226 (23.4
274 (28.3)

69 (9.2)
157 (21.3)
648 (94)

680 (90.8)
580 (78.7)
41 (6)

0 (0)
12 (1.6)
60 (8)

Prevalence of Intimate Partner Violence
Table 9 provides data for the prevalence of IPV. Patients who answered yes to any of the
five AAS questions were recorded as positive for having experienced IPV. The missing data
column consists of patients with an AAS screen marked “unable to answer” which typically
meant someone other than the staff member and patient was in the room. As noted earlier,
around a third of patients were not able to be screened for IPV. Research question one asked
what is the prevalence of IPV in a high-risk obstetrics population? According to this study, 5.6%
+/- 1.45% (4.09%-7.1%) of high-risk obstetrics patients at Methodist Women’s Hospital have
experienced IPV.

IPV

Table 9: Prevalence of Intimate Partner Violence
Before Exclusion (N=967)

After Exclusion (N=749)
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Yes N (%)

No N (%)

Missing N (%)

Yes N (%)

No N (%)

Missing N (%)

54 (5.6)

587 (60.7)

326 (33.7)

35 (7.8)

413 (55.1)

301 (40.2)

Perpetrator of IPV
Table 10 describes the relationship of the perpetrators of IPV for the patients who
provided that information for question two and three. Perpetrators were identified as: “expartner”, “ex-husband”, “partner”, “stranger”, “partner’s best friend”, or “ex-brother-in-law”. Of
the 54 patients who screened positive for IPV, only 9 patients (16.7%) indicated their
relationship to the perpetrator of IPV. Of those who indicated their relationship to the
perpetrator, it was most frequently a former partner who had perpetrated the IPV.
Table 10: Breakdown of Abuse Assessment Responses (N=9)
Abuse Assessment
Screen
Perpetrator of IPV
Partner
Former Partner
Acquaintance
Stranger
Other
Multiple
Total Who Specified

Frequency
1
5
0
1
2
0
9

Abuse Assessment Screen Data
Table 11 includes the frequency of each Abuse Assessment Screen question and percent
of total positive IPV screens. Of note, patients were able to voluntarily respond to any of the five
questions, so multiple responses are possible for each patient. Question 2 and 3 had follow-up
questions asking the patient to specify who had perpetrated the violence and how often; very few
patients responded to these follow-up questions. Only five patients shared how often the violence
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had occurred. Three patients stated it had happened once, one patient stated it had happened 30
times, and one patient stated it had happened 34 times. Only one patient specified where they had
been hit; this patient indicated they had been kicked in the belly by a child with which they
worked. Only nine patients responded who had perpetrated the violence (Table 10). There is no
composite score for the AAS scale. If patients indicated yes on any one of the five questions,
they were considered “positive” for intimate partner violence (McFarland et al., 1996). Fifty-four
out of 967 participants (5.6%) scored “positive” on this scale. Of those that scored positive, most
patients only answered Question 1; a large majority of patients (96.3%) responded yes to
question 1: have you ever been emotionally or physically abused by your partner or someone
important to you?
Table 11: Abuse Assessment Screen Data

Question 1: Have you ever been
emotionally or physically abused by your
partner or someone important to you?
Question 2: Within the last year, have you
been hit, slapped, kicked, or otherwise
physically hurt by someone?
Question 3: Since you’ve been pregnant,
have you been hit, slapped, kicked, or
otherwise physically hurt by someone?
Question 4: Within the last year, has
anyone forced you to have sexual
activities”?
Question 5: Are you afraid of your partner
or anyone you listed above?”

Frequency % of total
% of total
54 positive respondents
screens
52
96.3
5.4
5

9.3

.5

1

1.9

.1

5

9.3

.5

4

7.4

.4
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Outcome Data
Association between IPV and Maternal and Fetal Health Outcomes
Table 12 further provides information as to the statistical significance and direction of
significance of independent variables on IPV before and after exclusion of patients with missing
delivery data. Table 12 includes the p-values for all chi square tests for association between IPV
and all independent variables. P-values are included for the analysis performed on the data
before and after excluding patients with missing delivery data. Variables with a significant pvalue defined as less than .05 are highlighted in red. There are seven total significant variables.
The significant variables before exclusion are: BMI, STI, psychiatric disorder, birth weight for
twin A, ultrasound anomaly, insurance provider, and marital status. Significant variables after
exclusion of patients with missing delivery data are: psychiatric disorder, birth weight for twin
A, ultrasound anomaly, insurance provider, and marital status. BMI was borderline significant
before exclusion with a p-value of .010, and BMI became insignificant after exclusion of patients
with missing delivery data. Additionally, only 42 patients screened positive for a STI before
exclusion, and STI became insignificant after exclusion. No patients had a bone fracture or head
trauma diagnosis which explains why no p-value exists for these two variables. Finally, during
data analysis, variables that are bold had one cell (>20%) with an expected count less than 5
which meant that a Fisher’s Exact Test result was recorded rather than the Pearson Chi-Square
Test result.
Research question two asked: is IPV associated with adverse pregnancy outcomes and/or poor
birth outcomes? Data from this study show that BMI >25, STI, psychiatric disorder, low birth
weight, ultrasound anomaly, a non-employer-based insurance provider, and non-married status
are associated with IPV.
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Association Between IPV and Demographic and Birth Outcome Variables
Table 12 summarizes the direction of significance for six significant variables and eight
non-significant variables. For the significant variables, to determine direction of significance,
SPSS crosstabulation results were examined. For example, for patients who tested positive for an
STI before exclusion, patients with an STI who screened positive for IPV were divided by the
total number of patients who screened positive for IPV which was 8/51 or 15.7%. Then, patients
with an STI who screened negative for IPV were divided by the total number of patients who
screened negative for IPV which was 22/563 or 3.9%. Since 15.7% is greater than 3.9%, it is
reasonable to conclude that a diagnosis of an STI is associated with IPV. This same reasoning
was applied to all variables.
Table 13 provides data from the independent t tests that were conducted on BMI and age.
An independent t test was conducted to determine if there was a difference in IPV between
patients with a BMI≥25 and patients with a BMI<25. Results showed that there was a
statistically significant difference between patients without IPV (n=585, M=29.5, SD=8.2) and
patients with IPV (n=54, M=32.56, SD=9.02), t (637)= -2.581, p=0.01. The 95% confidence
interval of the difference was -5.36 - -0.73. Patients with IPV had a slightly higher BMI with a
mean of 32.6 than patients without IPV whose mean BMI was 29.5. Next, an independent t test
was conducted to determine if there was a difference in IPV between patients aged ≥35 years old
and patients aged <35 years old. There was not a statistically significant difference in mean age
between patients without IPV (n=587, M=32.08, SD=5.381) and patients with IPV (n=54,
M=31.72, SD=5.97), t (639)= 0.463, p=0.643, 95% CI for difference= -1.159-1.875). After
exclusion of patients with missing delivery data, neither BMI nor age were shown to be
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statistically significant. There was no statistically significant difference between mean BMI in
patients without IPV (n=411, M=28.996, SD=7.502) and patients with IPV (n=35, M=32.271,
SD=9.996), p=.066. Similarly, there was also no statistically significant difference in mean age
between patients without IPV (n=413, M=32.83, SD=5.107) and patients with IPV (n=35,
M=32.03, SD=6.100), p=0.381.

Table 12: Association Between IPV and Demographic and Birth Outcome Variables
Before Exclusion (N=967)
After Exclusion (N=749)
+IPV
+IPV% -IPV
-IPV% P+IPV
+IPV% -IPV
value
Significant
Variable
STI
8/51
Psychiatric 21/52
Disorder
BWA <
10/34
2.499kg
US
11/54
Anomaly
Non-EBHI
22/54
Insurance
Non31/54
Married
Marital
Status
Non-Significant Variable
PTL
4/38
PPROM
0/38
Hospitaliza 7/38
tion Before
Delivery
Pain
2/51
Disorder
GA
24/36
APGAR A5

33/34

15.7 22/563
40.4 96/565

3.9 0.002 4/35
17 <0.001 14/35

-IPV% p-value

11.4 18/413
40 73/413

4.4
17.7

0.083
0.001

29.4 64/414

15.5

0.035 10/34

29.4 62/411

15.1

0.029

20.1 60/587

10.2

0.019 10/35

28.6 45/413

10.9

0.006

40.7 126/587

21.5

0.001 14/35

40 72/413

17.4

0.001

57.4 149/585

25.6 <0.001 19/35

52.3 82/413

19.9

<0.001

10.5 42/428
0 23/423
18.4 94/427

9.8
5.4
22

0.781 4/35
0.242 0/35
0.607 7/35

11.4 37/413
0 23/413
20 90/413

9
5.6
21.8

0.547
0.241
0.805

3.9 27/564

4.8

1 2/35

5.7 24/413

5.8

1

66.6 325/421

77.2

0.153 24/35

78.5

0.178

97 399/410

97.3

1 33/34

68.6 324/41
3
97 398/40
9

97.3

1
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GDM
DM

Variable

BMI + no IPV

5/54
2/54

9.3 85/913
3.7 22/913

0.99 3/35
0.392 2/35

8.6 43/413
5.7 14/413

10.4
3.4

585

29.52

8.22

54

32.56

9.02

Age+ no IPV

587

32.08

5.381

54

31.72

-2.58

637

.010

-5.36 - -0.73

.463

639

.643

-1.159-1.875

5.973

After Exclusion of Patients with Missing Delivery Data (n=749)
BMI + no IPV

411

28.996

7.50

BMI + yes IPV

35

32.27

9.996

Age+ no IPV

413

32.83

5.107

Age+ yes IPV

1
0.36

Table 13: Association Between IPV and BMI and Age
N
Mean
Standard
t
df
Sig
95% CI for difference in
Deviation
mean
Before Exclusion of Patients with Missing Delivery Data (n=967)

BMI+ yes IPV

Age+ yes IPV

9.3
2.4

35

32.03

-1.894

37.3

.066

-6.779-0.228

0.878

446

.381

-0.994-2.597

6.100

Summary of Results
The first research question asked: what is the prevalence of IPV in the MFM population at
Methodist Perinatal Center? According to a survey of 967 patients, the prevalence of IPV in the
MFM population at Methodist Women’s Hospital is 5.6%. The prevalence of 5.6% is somewhat
higher than the 2.2% +/- 0.08% (1.4-3%) that was estimated prior to data collection based on
previous studies. Overall, the fact that this study finds a higher prevalence of IPV than was
expected highlights how underreported IPV is. The second research question asked: Is IPV
associated with adverse pregnancy outcomes and/or poor birth outcomes? The variables that
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were found to be significant after exclusion of patients with missing delivery data are:
psychiatric disorder, birth weight for twin A, ultrasound anomaly, insurance provider, and
marital status.

Chapter 5: Discussion
Summary
According to this study, 5.6% of high-risk obstetrics patients at Methodist Women’s
Hospital have experienced IPV. Results showed that the percent of high-risk pregnant women in
the Omaha Metro that experience IPV was 2.4% higher than the expected 2.2% (CDC, 2017a).
The prevalence of 2.2% was chosen as a reference because the PRAMS survey covers both
physical and psychological violence and is a 50-state survey making it the most generalizable
data. The prevalence of 5.6% is also higher than the 3.2% statistic cited by Chisholm et al.
(2017a). However, the prevalence of 5.6% falls within the range of 3.9-8.7% that a majority of
studies report (Van Parys et al., 2014) but is lower than the prevalence of 3-30% reported by
Devries et al. (2010). To my knowledge, this is the first study to estimate the prevalence of IPV
in the MFM population of women.
The prevalence of 5.6% determined by this study is likely underestimating the true
prevalence of IPV in this population as IPV is often under-reported due to patients’ fear of
repercussions due to disclosure or embarrassment (Chisholm et al., 2017a; Hossieni et al., 2017;
James et al., 2013; Baird, 2015). Moreover, only one percent of domestic violence cases are ever
reported to the police (James et al., 2013). In this study, 33.7% of patients were not screened due
to another person’s presence in the room at the time of screening. Clearly, there is a need to
educate the staff to ensure the importance of the partner not being in the room when delivering
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the survey so that staff can safely administer the survey for all patients. In addition, even among
the patients who were screened, studies show patients are very hesitant to report IPV; only 21%
of women who have experienced IPV actually disclose their experience with IPV to a provider
(Chisholm et al., 2017b). Many more patients might have screened positive if all patients had
been screened and if patients felt comfortable disclosing IPV.
With regard to maternal and fetal health outcomes, data from this study show that BMI
≥25, STI, psychiatric disorder, low birth weight, ultrasound anomaly, a non-employer-based
insurance provider, and non-married status are associated with IPV. An association between IPV
and negative pregnancy outcomes were found which include: overweight BMI, sexually
transmitted infection, psychiatric disorder, low birth weight, and ultrasound abnormality.
Further, IPV is associated with non-married patients and patients who self-pay for insurance or
receive Medicaid. Several of the health outcomes found to be associated with IPV in this study
corroborate past studies. For example, several studies have found low birth weight to be
associated with IPV (Chen et al., 2017; Laelago et al., 2017; Chisholm et al., 2017a). Chen et al.
(2017) found that a NICU admission is associated with IPV. Studies have shown STIs and
psychiatric disorders to be associated with IPV (Chisholm et al., 2017a; Zachor et al., 2018).
Chisholm et al. (2017a) report that physical inactivity (which can lead to a higher BMI) is
associated with IPV. Further, Yakubovich et al. (2018) found that identifying as married is a
protective factor against IPV and James et al. (2013) report that being single is associated with
IPV. The finding from these previous studies corroborate the finding from this study that nonmarried status is associated with IPV in the MFM population. The only variable found to be
significant in this study that has not been reported in other studies was ultrasound abnormality.
This may be because most studies on IPV in pregnancy focus on normal pregnancies that,
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seemingly, would not have an ultrasound abnormality. This study included ultrasound
abnormality as maternal fetal medicine specialists are more likely to encounter patients whose
pregnancies contain ultrasound abnormalities. This finding may be new and subject for future
research. For all of these patients experiencing IPV, their future health trajectories will likely be
negatively affected by IPV. Based on this study, it is clear that it is vitally important to screen all
patients- especially high-risk pregnant patients- for IPV.
With regard to risk factors, research shows young women, typically under age 25, are at
higher risk for IPV (Yakubovich et al., 2018). However, this study did not show that age was
statistically significant. For this study, patients of advanced maternal age are more clinically
significant in the MFM population than being a younger age. When it became necessary to split
patient ages into two groups for data analysis, the age of 35 was chosen as the delineating point
because being 35 or older is defined as advanced maternal age. Additionally, the mean age for
patients in this study was 32 which also justified an age cut-off of 35. Perhaps if the age cutoff
had been lower, that might have shown significance as younger women have been shown to be at
higher risk for IPV than older women. Further studies could create a lower age cutoff to examine
this. Also, Chisholm et al. (2017a) state that certain health disparities according to race,
ethnicity, education, income, and age are associated with IPV. Of these variables, this study only
showed a non-employer-based insurance provider to be statistically significant. In the United
States, since most people rely on their job for health insurance (Berchick et al., 2019), health
insurance can be used as a surrogate for employment and, thus, socioeconomic status. Since
having non-employer-based health insurance (self-pay or Medicaid) was statistically significant
in its association to IPV, it stands to reason that patients of lower socioeconomic status are at
higher risk for IPV in this study population. Additionally, as this study population was not very
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diverse in ethnicity, race, or language spoken, future studies would benefit from a more diverse
population. If this study were to include patients from other health centers in Omaha that have a
larger percentage of a diverse patient population, that would provide more data about the patient
population of the Omaha Metro Area as a whole.
Additionally, studies have found that abuse before pregnancy is associated with IPV
(James et al., 2013). Among the patients in this study who screened positive for IPV, 96.3% of
them screened positive for Question 1 of the AAS which asks if a patient has ever been
emotionally or physically abused by a partner or someone important to them. This indicates that
a majority of the patients in this study that screened positive for IPV had experienced IPV
sometime during their life prior to or during their current pregnancy. The results of this study
seem to support prior findings that abuse before pregnancy is associated with IPV. Another risk
factor for IPV is having experienced violence by a family member which is an adverse child
event (Ludermir et al., 2017). While only two patients of this cohort indicated their former IPV
exposure was from a family member, that is not clinically insignificant. This finding highlights
the need for providers to holistically approach patients and further understand how the lifespan
affects a patient- with particular focus on how exposure to adverse childhood events can impact a
person later in life.
Furthermore, some of the effects of IPV that have been reported in the literature are bone
fracture, laceration, head trauma, STI, pain disorder, and psychiatric disorder (Chisholm et al.,
2017a). Of these effects, STI and psychiatric disorder were statistically significant in this study.
It might be important for staff and providers at this clinic to take these findings in consideration
when working with patients with STIs and/or psychiatric disorders as they may be experiencing
IPV. Adverse fetal outcomes that have been shown to be related to IPV are small for gestational
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age, preterm birth, and low birthweight (Chisholm et al., 2017a). Specifically, many studies have
shown low birthweight to be associated with IPV (Chisholm et al., 2017a; Chen et al., 2017;
Laelago et al., 2017). Results from this study indicate that IPV is associated with infants with a
low birth weight. This is significant because low birthweight infants are at risk for a multitude of
health issues (American Academy of Pediatrics, 2017). For example, having an infant with low
birth weight and its effects could place stress on the mother and potentially strain the mother’s
relationship with her partner and exacerbate any IPV that may be occurring. One study found
that mothers who have infants born with a very low birth weight experience stress due to related
complications; this stress negatively affects mothers, families, and infants (Helle et al., 2018).
When considering low birth weight infants as similar to very low birth weight infants, it is
possible that mothers with low birth weight infants would also experience stress, thus, negatively
affecting the mother, infant, and family structure. Further, Ellis et al. (2008) found that after birth
women who had experienced IPV continue to report higher levels of stress and less partner
support than women who do not experience IPV. They found that women who have experienced
IPV seek healthcare more often for their infants than women who have not experienced IPV; the
study hypothesized that the IPV may result in the infants and their mothers experiencing more
illness. Any of this additional stress could exacerbate any IPV that might be occurring.
Strengths and Limitations
One strength of this study is that through the partnership with physicians at Methodist
Perinatal Center, the full five-question abuse assessment screen was implemented into the
electronic health record for the entire Methodist Women’s Hospital system. As of January 2019,
all patients receiving care for a first obstetrics visit are to be screened for IPV with the AAS.
Prior to implementing the AAS, the IPV screen was only a one-question, unvalidated screen.
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Another strength of the study is the choice of the screening instrument. The AAS is short which
decreases survey fatigue. Also, the survey includes various forms of abuse including both
physical and psychological abuse which not all IPV screening instruments do. Further, the AAS
includes a question specifically about pregnancy; not all IPV surveys include a question about
pregnancy. Additionally, this study is one of the first to examine IPV in the MFM population,
providing valuable groundwork for further work on IPV in this patient population.
There are several limitations of this study. First, it is unclear if patients who only
presented for an ultrasound were excluded from the initial sample. Support staff ran an analysis
of every patient that was seen for a first OB visit within the study time parameters, but some
visits that were for ultrasound-only might have been included unintentionally which may have
contributed to the 218 patients that have missing delivery data. Second, confounding factors
likely made a difference in patients’ understanding of the survey questions. The confounding
variable is patient understanding of “abuse” or “emotional abuse” which possibly resulted in
underreporting. Also, two patients who screened positive for IPV indicated that their exposure
was due to their profession being around children who kicked them; while that circumstance
technically answers the AAS questions, that response does not fall under the definition of IPV or
interpersonal abuse. In this way, those two patients were false positives. While not a large
number, that still indicates there was some confusion on patients’ behalf regarding the purpose of
the questions. This points to either the need for more training for the staff delivering these
questions or the need to choose an IPV survey instrument that better clarifies the screening
questions. Also, the AAS allows for patients to select options “stranger” and “acquaintance” for
the identity of the perpetrator of the IPV. Neither strangers or acquaintances fall under the
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definition of an intimate partner. In this way, the AAS includes both IPV and interpersonal
violence, which is a consideration for future studies when selecting a survey instrument.
Further, another limitation is the inability to screen patients alone. If a woman was not
able to be screened alone, the staff were instructed not to administer the survey questions for the
patient’s safety which resulted in a smaller sample size. There are three likely possibilities for
patients not being able to be screened alone: the patient might have wanted another person in the
room with them, persons accompanying the patient might have insisted on accompanying the
patient and disregarded the request of staff members to speak to the patient alone, and/or staff
members might have failed to provide clear instructions to the patient and support person or did
not have the skills to separate the patient from the person. Any one of these or other reasons
could have contributed to a third of patients not being able to be screened alone. However, even
if patients were able to be screened alone, research shows that patients often do not feel safe
reporting IPV (Chisholm et al., 2017a; Hossieni et al., 2017; James et al., 2013; Baird, 2015;
Fletcher et al., 2016). For example, in this study 54 patients screened positive for IPV. However,
six other patients who did not screen positive for IPV in this study had diagnosis codes in their
chart indicating a history of IPV even to the point that one patient requested a cesarean delivery
due to the patient’s past IPV-related trauma.
With 33.7% of patients not being screened, there is improvement to be made to ensure
staff are able to separate patients from support persons (often partners) to conduct the survey
confidentially. Another issue indicating a need to educate the support staff is that some staff were
still using the previously-used IPV screen. Those patients had to be excluded, decreasing the
sample size of this study. Educating the support staff on IPV and the AAS might help alleviate
this confusion. Staff also weren’t trained on how to provide feedback to patients’ questions about
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the questionnaire. Past studies have shown that training nursing and support staff about IPV and
the screening survey is well received (Burmele et al., 2018). Perhaps, the staff at Methodist
Perinatal Center can undergo training on IPV and the AAS which might lead to an increase IPV
screening rate. Training of providers has also been shown to increase their communication with
patients about IPV; in the future, providers at Methodist Perinatal Center could also undergo IPV
training (Zachor et al., 2018).
Further, due to personnel constraints, a screen during subsequent trimesters was not
possible during this research study which limited this study’s ability to capture all patients who
experienced IPV during the entirety of their pregnancy. However, future research projects could
include screens during each pregnancy trimester to ensure that patients are not being missed if
they experience IPV later in their pregnancy. Also, certain demographic information such as
gender identity and sexual orientation are not included as the electronic health record utilized
does not provide this information. As we are unable to collect this information at this time, this is
an area for future research projects to examine. Additionally, there was no plan in place for the
patients who screened positive other than following clinical guidelines and providing local
resources- namely information about the Women’s Center for Advancement, the main resource
center for people who have experienced interpersonal violence in the Omaha Metro Area. In the
future, a more robust plan should be in place in the event of a positive IPV screen. Another
limitation is that staff had not been trained in the concepts of trauma-informed care; this is
something which the clinic could pursue in the future.
Moreover, there are several limitations to a non-probability sampling method. Nonprobability sampling methods are not as robust as probability sampling methods. While it is the
easiest form of sampling to complete, convenience sampling creates the potential for bias within
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the data collected. Since convenience samples are not randomized, there is no way to reduce bias
within the sample. Since the sample data is only coming from one clinic, there is no way to
generalize the data to other populations. Because there is no randomization within convenience
sampling, that makes it a weaker sampling method. Future studies can an attempt to incorporate
more robust sampling methods. Further, only one hospital system was sampled due to time
constraints and personnel constraints. Including other hospitals in the study in an effort to
increase generalizability of data would require participation and cooperation from multiple
departments and personnel.
Additionally, future research could include a mixed methods study by gathering
qualitative data from interviews with patients who screen positive and staff who administer the
survey. This could provide valuable information that could help guide decision-making regarding
intervention strategies for future patients. Additionally, another area for future research would be
to examine the difference in proportion screened for IPV before the Abuse Assessment Screen
was incorporated into the EMR at Methodist Perinatal Center and after the incorporation of the
screen. Prior to this study, the Methodist Perinatal Center included a one-question unvalidated
screen for IPV. After incorporating a more robust and standardized screening survey and
procedure, it is hypothesized that there would be an increase in screening after incorporation of
the Abuse Assessment Screen into the EMR. This question highlights the effects of various
forms of EMR on screening for any health condition. Depending on the hospital system and
which EMR a hospital system chooses to use, there may be a difference in the robustness of
screening tools implemented by a given healthcare system.
Interpretation
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Data from this study indicates that more patients than expected are experiencing IPV at
Methodist Women’s Hospital as this study found that IPV was 3.4% higher than the expected
2.2% (CDC, 2017a). Often, the IPV discourse focuses on populations that are known to be at risk
for IPV. The demographics of the patient population at Methodist Perinatal Clinic was shown to
be largely white, English-speaking, non-Hispanic, employed, married, and with employer-based
health insurance which is not largely representative of the populations who are known to be at
greater risk for IPV. One takeaway from this study is that IPV can and does exist in all patient
populations- even among patients who might be among the demographics that carry less risk
factors for IPV such as patients who are white, English-speaking, non-Hispanic, employed, and
married. Again, it is clear that it is vitally important that all patients be screened for IPV. There is
always the potential to encounter a patient who has experienced IPV and to intervene and
improve outcomes.
Generalizability
This study took place at one clinic in Omaha, NE. Unfortunately, the Methodist Perinatal
Center is not representative of the entire Omaha Metro Area population as the demographic
make-up of patients at Methodist Perinatal Center does not reflect the demographic make-up of
the Omaha Metro Area. Including more hospital systems in future studies would help to diversify
the patient population to make it more generalizable to the Omaha Metro Area. However, even
then that would not make it generalizable to the overall population of the United States. Future
studies could consider including hospitals from multiple states to ensure the greatest
generalizability. This often requires funding and can be logistically challenging, but it would
provide invaluable information about how many high-risk obstetrics patients are experiencing
IPV and how that is affecting them.
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Conclusion
The research question for this study was born out of a passion for investigating intimate
partner violence among high-risk pregnant patients. As IPV has not been thoroughly studied
among the high-risk pregnant population, a quantitative assessment of the prevalence of IPV in
the MFM population was helpful before attempting a qualitative in-depth analysis of the
population. Now that quantitative data has been obtained, qualitative data from patients who
screen positive for IPV could be obtained in the future that would further inform IPV
intervention strategies. Further, it is evident from the findings of this study that the life course
theory can inform thinking about IPV in the setting of pregnancy- including high-risk pregnancy.
Pregnancy is an important transition in the lives of many women that has the potential to either
positively or negatively alter a woman’s life course trajectory and, possibly, her future
offspring’s trajectory. Further, if a woman experiences IPV during her pregnancy, that more than
likely negatively affects her trajectory. The maternal fetal medicine patient population is already
at high risk of experiencing a negative change in their health trajectory after pregnancy. Thus, an
understanding of intimate partner violence is vitally important for all health care personnel
caring for high-risk pregnant patients.
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